US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

CGON CG Oncology Inc

33.47

1.13 (3.49%)

22 Nov 2024 - Cerrado

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/29/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Hong Fang Song, Simone

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

CG Oncology (NASDAQ:CGON)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Haga Click aquí para más Gráficas CG Oncology.

CG Oncology (NASDAQ:CGON)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024

Haga Click aquí para más Gráficas CG Oncology.

Noticias sobre CG Oncology Inc CGON

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Miércoles 20 de Noviembre 2024 (3 días hace) • GlobeNewswire Inc.

Form 8-K - Current report
Martes 12 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
Martes 12 de Noviembre 2024 (2 semanas hace) • GlobeNewswire Inc.

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
Lunes 11 de Noviembre 2024 (2 semanas hace) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Viernes 8 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 7 de Octubre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 7 de Octubre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 7 de Octubre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 7 de Octubre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 7 de Octubre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 30 de Agosto 2024 (3 meses hace) • Edgar (US Regulatory)

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Viernes 30 de Agosto 2024 (3 meses hace) • GlobeNewswire Inc.

Más de CG Oncology Inc Artículos de Noticias

Almacenes Exito

The Progressive

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones